常规心脏磁共振中肝脏T1成像与细胞外容积定量的可行性
本研究回顾性分析135例接受心脏磁共振的患者,评估肝脏T1和细胞外容积(ECV)在淀粉样变性和系统性疾病中的表现。结果显示,淀粉样变性患者肝脏T1和ECV最高,系统性疾病次之,对照组最低,且肝脏T1与ECV正相关。结论认为在心脏磁共振中定量肝脏ECV可行,值得进一步纵向研究早期肝病检测。
要点
- 肝脏T1和ECV在心脏淀粉样变性患者中最高,系统性疾病次之,对照组最低。
- 肝脏T1与ECV呈正相关(R2=0.282,p<0.0001),提示可联合评估肝纤维化。
- 所有患者肝功能正常且无临床肝病,提示肝脏T1/ECV可能检测亚临床受累。
关键影像表现/征象
- 心脏淀粉样变性组心肌T1为1169±92 ms,系统性疾病组为1101±53 ms,对照组为1027±73 ms(p<0.0001)。
- 心脏淀粉样变性组心肌ECV为0.47±0.11,系统性疾病组为0.31±0.05,对照组为0.27±0.04(p<0.0001)。
- 心脏淀粉样变性组肝脏T1为646±101 ms,系统性疾病组为660±93 ms,对照组为595±58 ms(p<0.0001)。
- 心脏淀粉样变性组肝脏ECV为0.38±0.08,系统性疾病组为0.37±0.05,对照组为0.31±0.03(p<0.0001)。
- 肝脏T1与肝脏ECV呈正相关(R2=0.282,p<0.0001)。
临床应用与阅片要点
- 在心脏磁共振检查中可顺便测量肝脏T1和ECV,有助于发现淀粉样变性或系统性疾病患者的亚临床肝脏受累。
- 需注意肝脏T1和ECV的测量需基于同一序列和公式,且本研究中患者肝功能正常,解读时应结合临床。
局限性
- 本研究为回顾性研究,样本量有限,且未纳入肝功能异常患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Cardiac magnetic resonance imaging (CMR) is commonly obtained to evaluate for myocardial infiltrative disorders and fibrosis. Pre- and post-Gadolinium contrast T1-mapping sequences are employed to estimate interstitial expansion using extracellular volume fraction (ECV). Given the proximity of the liver to the heart, T1 and ECV quantification of the liver is feasible on CMR. The purpose of this study was to evaluate for hepatic measures of fibrosis and interstitial expansion in patients with amyloidosis or systemic disease on CMR.
MATERIALS AND METHODS: Myocardial and hepatic native T1 values were measured retrospectively using a cardiac short axis modified Look-Locker inversion recovery sequence. Myocardial and hepatic ECV were calculated using pre- and post-contrast T1 and blood pool values according to the following formula: ECV = (Δ(1/T1) myocardium or liver and/or Δ(1/T1) blood)x(1 - hematocrit). Patients were divided into three cohorts by final diagnosis: amyloidosis, systemic disease (e.g. sarcoid, scleroderma), and controls (EF > 50, no ischemia).
RESULTS: Of the 135 patients who underwent CMR, 22 had cardiac amyloidosis (age 59.9 ± 12.6 yrs, 41% female), 20 had systemic disease (age 50.9 ± 13.4 yrs, 35% female), and 93 were controls (age 49.5 ± 17.3 yrs, 50% female). Myocardial T1 and ECV values were highest for patients with amyloid, second highest for systemic disease, and least for controls (T1: 1169 ± 92 vs 1101 ± 53 vs 1027 ± 73 ms, p < 0.0001; ECV: 0.47 ± 0.11 vs 0.31 ± 0.05 vs 0.27 ± 0.04, p < 0.0001). Hepatic T1 and ECV were similarly higher in patients with amyloid and systemic disease compared to controls (T1: 646 ± 101 vs 660 ± 93 vs 595 ± 58 ms, p < 0.0001; ECV: 0.38 ± 0.08 vs 0.37 ± 0.05 vs 0.31 ± 0.03, p < 0.0001). There was a positive correlation between hepatic T1 and ECV (R2 = 0.282, p < 0.0001). No patients had abnormal liver function tests or clinical liver disease.
CONCLUSION: Hepatic ECV quantification on CMR in patients with amyloidosis and systemic disorders is feasible. Further longitudinal investigation regarding detection of early or subclinical liver disease is warranted.
引用
- Dolan RS, Stillman AE, Davarpanah AH, et al. Feasibility of Hepatic T1-Mapping and Extracellular Volume Quantification on Routine Cardiac Magnetic Resonance Imaging in Patients with Infiltrative and Systemic Disorders. Acad Radiol. 2021. PMID: 34702675. doi:10.1016/j.acra.2021.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。